OncoMatch/Clinical Trials/NCT07232654
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Is NCT07232654 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Iparomlimab/Tuvonralimab and Cisplatin for locally advanced cervical cancers.
Treatment: Iparomlimab/Tuvonralimab · Cisplatin — This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage T3A-4A (III-IVA) (FIGO 2018)
FIGO 2018 stage T3a-4a (III-IVA), N1 (positive lymph node metastasis on CT/MRI with short-axis ≥1 cm, or PET-CT showing one or more lymph node metastases with SUVmax ≥2.5), M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors or other tumor immunotherapy
Cannot have received: tumor immunotherapy
Prior treatment with immune checkpoint inhibitors or other tumor immunotherapy
Lab requirements
Blood counts
anc ≥1.5 ×10⁹/l; platelets ≥100 ×10⁹/l; hemoglobin ≥90 g/l (no blood transfusion or growth factor support within 7 days)
Kidney function
crcl ≥50 ml/min (cockcroft-gault formula), urine protein <2+ or 24h <1.0 g
Liver function
total bilirubin ≤1.5×uln; ast and alt ≤2.5×uln
Cardiac function
lvef ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify